How to buy, sell and short AstraZeneca shares

About AstraZeneca

AstraZeneca (LSE: AZN) is a global biopharmaceutical company headquartered in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines. The company operates across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare disease. It is the UK's largest company by market capitalisation and a FTSE 100 constituent, with a market capitalisation of approximately £205 billion as of July 2026.

The company was formed in 1999 through the merger of Astra AB and Zeneca Group. It trades under the AZN ticker on the London Stock Exchange as its primary listing, with secondary listings on the NYSE and the OMX Stockholm Exchange. The NYSE listing means AZN shares are also accessible for UK investors seeking ISA-eligible holdings through a US exchange route. Q1 2026 total revenue was around £11.4bn, up 13% year on year and ahead of consensus.

AstraZeneca Q1 2026 results and pipeline

AstraZeneca’s Q1 revenue was driven by double-digit growth in oncology and rare disease. Product revenue was approximately £11.3 billion and core operating profit rose 12% at constant exchange rates. The company reconfirmed its full-year 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates. Sterling figures converted at GBP/USD 1.3419 (Yahoo Finance, 9 July 2026); AstraZeneca reports in US dollars.

CEO Pascal Soriot described the company as being in a 'catalyst-rich period', noting positive Phase III readouts for Tozorakimab in COPD and Efzimfotase alfa in Hypophosphatasia since the previous quarterly results. In July 2026, AstraZeneca's drug for autosomal dominant polycystic kidney disease received orphan status designation, adding to the regulatory milestones in its pipeline. A Phase IIb trial of its obesity pill Elecoglipron showed patients lost 10.5% of body weight after 26 weeks, positioning the company in the fast-growing GLP-1 obesity treatment market alongside Novo Nordisk and Eli Lilly. Q2 2026 results are due on 29 July 2026.

How to buy AstraZeneca shares

1. Decide how you want to invest

You can invest in AstraZeneca by buying shares outright, which gives you direct ownership, dividend entitlement and shareholder rights. Alternatively, you can trade AstraZeneca shares using spread bets or CFDs to speculate on the share price without ownership. Spread bets and CFDs use leverage, which amplifies both gains and losses, and are not suitable for long-term portfolio building. 69% of retail investors lose money when trading spread bets and CFDs with us, so proper risk management strategies are essential.

2. Choose an account type

For long-term investment, a stocks and shares ISA shelters gains and dividend income from UK capital gains tax and income tax permanently within the £20,000 annual allowance. AstraZeneca shares are ISA-eligible through its LSE primary listing. A share dealing account suits amounts above the ISA limit. For new investors, a step-by-step beginner's approach to buying shares covers the full process.

3. Research the current position

Review AstraZeneca's most recent results, analyst consensus, pipeline milestones and the broader pharmaceutical sector outlook. Key metrics to assess include revenue growth by therapy area, core EPS growth, pipeline phase progression and any upcoming data readouts or regulatory decisions. The company's investor relations website at astrazeneca.com is the primary source for financial results and pipeline data.

4. Place your order

Search for AZN on our platform. Review the current bid and ask price and the spread. For ISA-eligible purchases through the LSE listing, choose the share dealing account or ISA. Set your order type (market or limit) and confirm. Settlement on LSE shares is T+2.

How to sell AstraZeneca shares

Selling AstraZeneca shares held in a share dealing account or ISA follows the same process as buying: search for AZN, select 'sell', choose the number of shares and confirm. For positions held outside an ISA, capital gains above the £3,000 annual allowance (2026/27) are subject to CGT at 18% (basic rate) or 24% (higher rate). AstraZeneca's dividend qualifies as income above the £500 annual allowance in the normal way outside an ISA.

Timing decisions around earnings releases, particularly the quarterly results and pipeline data readouts that AstraZeneca frequently delivers, can materially affect the price at which you sell. Shares can move sharply around unexpected trial results, regulatory decisions or earnings surprises. A stop-loss order can limit downside if you are concerned about a sudden adverse move.

How to short AstraZeneca shares

Going short on AstraZeneca means taking a position that profits if the share price falls. This is not possible with direct share ownership, but is straightforward using spread bets or CFDs. A short spread bet on AZN would gain value if the share price falls from the opening level to the closing level, multiplied by your stake per point.

Reasons an investor might consider shorting AstraZeneca include: an expectation that a Phase III trial will produce disappointing data, concerns about patent expiry on major revenue-generating drugs, an adverse FDA or MHRA regulatory decision, or a view that the current valuation is too high relative to earnings growth. Short selling carries theoretically unlimited loss potential if the share price rises, making position sizing and stop-loss management essential.

What drives the AstraZeneca share price?

• Clinical trial data: Phase II and III readouts for drugs in the pipeline are the most significant near-term price movers. Positive data typically drives the share price up sharply; negative data can cause significant declines.
• Regulatory approvals and rejections: FDA and MHRA decisions on new drug applications, label expansions and post-market requirements directly affect revenue forecasts and investor sentiment.
• Revenue and earnings growth: quarterly results against consensus expectations move the share price. AstraZeneca has consistently delivered double-digit revenue growth in recent years, which has supported the premium valuation relative to sector peers.
• Dividends: AstraZeneca pays a progressive dividend in US dollars. Changes to dividend policy or yield relative to alternatives affect income-focused shareholders. For context on how dividend investing works at FTSE level, Lloyds' dividend history provides a UK comparison of dividend-focused stock analysis.
• Pipeline milestones: the breadth and depth of AstraZeneca's pipeline, which extends across multiple therapy areas with several late-stage programmes, is the primary basis for its premium valuation. Investors track anticipated readouts closely.
• Currency: the company earns and reports in US dollars. GBP/USD movements affect the sterling share price and dividend income for UK investors.

AstraZeneca share FAQs